Navigation Links
Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
Date:4/29/2010

SEATTLE, April 29 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros, will present at the Deutsche Bank 35th Annual Health Care Conference in Boston on May 4, 2010 at 2:50 p.m. EDT.  The presentation will be webcast.  The live or archived webcast can be accessed on the "Events" page of the Company's website at www.omeros.com.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery™ platform and one from its Addiction program, the most advanced of which is in Phase 3 clinical trials. Omeros may also have the near-term capability, through its GPCR program, to add an unprecedented number of wholly new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of antibody and small-molecule preclinical programs targeting inflammation and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
9. Omeros Commences Initial Public Offering of Common Stock
10. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
11. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... Resoundant, Inc. is pleased ... centers around the U.S. that offer MR Elastography for liver fibrosis staging. ... biopsy for staging liver fibrosis assessment. , “MRE:connect was created in response to ...
(Date:7/20/2017)... ... July 20, 2017 , ... VIC Technology Venture Development™ (VIC™), ... of directors. This addition continues to strengthen and diversify VIC’s board. , "We ... Chairman. “He is a highly accomplished business executive with a broad range of experience ...
(Date:7/20/2017)... San Diego, CA (PRWEB) , ... July 20, 2017 , ... ... to corporate governance at its 27th annual Director of the Year Awards. , The ... Hyatt Regency La Jolla. This annual event celebrates directors who have made significantly ...
(Date:7/18/2017)... ... July 18, 2017 , ... Sourcing custom glass or ... needs and has the capabilities to properly execute your job can take many hours ... is a sourcing portal designed to showcase the company’s capabilities and core custom ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):